{"id":164716,"date":"2026-04-27T10:17:41","date_gmt":"2026-04-27T08:17:41","guid":{"rendered":"https:\/\/www.startupbusiness.it\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/"},"modified":"2026-04-27T10:25:42","modified_gmt":"2026-04-27T08:25:42","slug":"from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/","title":{"rendered":"From patient to pioneer: the entrepreneur revolutionising organ transplants"},"content":{"rendered":"\n

Gabriel Liguori\u2019s earliest memory is not of childhood games, but of a hospital ward. At just two years old, in Brazil, he was awaiting a delicate heart operation to partially correct the congenital heart defect he had been born with. <\/p>\n\n

Hospital wards did not put him off; on the contrary, they became places of fascination for him. The doctors, the procedures and the rhythm of hospital life sparked his curiosity and fuelled his determination to one day help other patients facing similar challenges. <\/p>\n\n

\u201cI never thought I\u2019d do anything other than be a doctor,\u201d recalls Liguori.<\/p>\n\n

That determination led him to enrol at the Faculty of Medicine at the University of S\u00e3o Paulo, where he immediately joined the cardiac surgery team that had treated him as a child. He experienced their world from the inside: observing operations, conducting research and learning the medical profession step by step. <\/p>\n\n

From doctor to entrepreneur<\/strong><\/h2>\n\n

After completing his PhD in the Netherlands, Liguori returned to Brazil to devote himself to research in tissue engineering and regenerative medicine. These fields hold the promise of a future in which replacement organs can be grown in the laboratory, reducing reliance on scarce donors and the risk of rejection. <\/p>\n\n

But he soon discovered a fragmented landscape: laboratories lacking standardised equipment, expensive biomaterials, and results that were difficult to replicate. To transform regenerative medicine from promise to practice, an infrastructure was needed \u2013 a platform capable of democratising tissue engineering on a global scale. <\/p>\n\n

This insight led to the creation of TissueLabs, a company that provides biofabrication platforms for creating over 15 types of tissue. From cardiovascular models to skin and liver, TissueLabs offers proprietary biomaterials and 3D bioprinting technologies that make experimentation faster, more cost-effective and more reliable. <\/p>\n\n

For Liguori, TissueLabs is not just a business. It is a life\u2019s work born out of his personal and professional experience. <\/p>\n\n

Changing patients’ lives<\/strong><\/h2>\n\n

The implications of TissueLabs\u2019 work are far-reaching. In the future, patches of cultured tissue could repair congenital heart defects in children, reducing the reliance on transplants. <\/p>\n\n

Already, pharmaceutical companies are using the platform to test drugs on tissues similar to human tissue, thereby avoiding animal models, reducing costs and addressing ethical concerns.<\/p>\n\n

Thanks to its guaranteed reproducibility, TissueLabs accelerates research: from S\u00e3o Paulo to Zurich and on to Shanghai, researchers can work with identical biomaterials, compare results and build on a common foundation. This collaborative ecosystem shortens the path from laboratory experimentation to clinical application. <\/p>\n\n

Whilst the transplantation of cultured organs remains a long way off, intermediate applications \u2013 ranging from drug testing and disease models to regenerative therapies \u2013 are already transforming patient care. TissueLabs sits at the intersection of science and the market, offering both immediate benefits and a long-term vision. <\/p>\n\n

Liguori and co-founder Emerson Moretto were soon joined by angel investor Eduardo Zylberstajn, the father of a child with congenital heart disease, who has formed a deep connection with the company\u2019s mission.<\/p>\n\n

Commercial potential and fundraising<\/strong><\/h2>\n\n

TissueLabs\u2019 commercial roadmap is divided into three phases, each of which is set to open up ever-wider markets. The first phase has resulted in the creation of a biofabrication platform \u2013 integrating proprietary hardware, software and biomaterials \u2013 to enable researchers to create tissues and organs in the laboratory, a market estimated to be worth one billion dollars. <\/p>\n\n

The second phase focuses on proprietary tissues for pharmaceutical research, particularly for cardiotoxicity testing, tapping into a market worth $10 billion. The third phase focuses on therapeutic tissues for transplants, a sector worth over $100 billion. <\/p>\n\n

The company is now transitioning from phase one to phase two, with the aim of launching cardiac tissue models within two years: a milestone that is expected to drive strong revenue growth. Today, universities and research institutes generate 70% of revenue, whilst the remaining 30% comes from private sector clients \u2013 ranging from start-ups to global giants such as L\u2019Or\u00e9al. TissueLabs already serves over 300 institutions worldwide and aims to increase its customer base tenfold, reaching 3,000 within three years. <\/p>\n\n

To support this expansion, the company is raising $3.5 million (3 million Swiss francs) in a new round of funding that is expected to close by June. Previously, TissueLabs had raised \u20ac1 million in angel and pre-seed funding and a further \u20ac1 million in grants. <\/p>\n\n

The new capital will be used to scale up operations, refine cardiac tissue models and strengthen global distribution.<\/p>\n\n

For investors, the appeal lies in TissueLabs\u2019 dual growth trajectory: immediate revenue from research applications and the transformative potential to revolutionise the transplant market.<\/p>\n\n

From Brazil to Switzerland<\/strong><\/h2>\n\n

For Liguori, setting up TissueLabs in Brazil was a natural choice: to contribute to his country\u2019s scientific landscape. But he soon came up against structural obstacles \u2013 a lack of funding, stifling bureaucracy and a fragmented innovation ecosystem. <\/p>\n\n

Venture capital for the biotechnology sector was virtually non-existent. Researchers struggled to access advanced biomaterials, particularly biomedical reagents subject to lengthy approval processes. Furthermore, Brazilian biotech products met with little success abroad, whilst the domestic market accounted for barely 1% of global research. <\/p>\n\n

With dwindling resources and pressure to meet sales targets, Liguori began to consider a move. The United States offered a vast market, but the financial and bureaucratic barriers were prohibitive. Switzerland, on the other hand, was accessible thanks to Liguori\u2019s dual Italian citizenship. <\/p>\n\n

The Canton of Ticino proved particularly attractive for plans to establish an innovation park dedicated to biofabrication. After initially setting up in Manno, near Lugano, TissueLabs moved to Bellinzona, next to the park. <\/p>\n\n

Today, the company\u2019s operational activities are based in Switzerland, whilst machinery production remains in Brazil, where lower labour costs ensure competitiveness.<\/p>\n\n

Opening in Hong Kong and mainland China<\/strong><\/h2>\n\n

TissueLabs\u2019 ambitions extend beyond Europe. Liguori recently took part in a two-week trade and investment mission to Hong Kong and mainland China, where the company did not yet have any clients or partnerships. <\/p>\n\n

The mission was organised by Swissnex, a government body that strengthens Switzerland\u2019s role as a global innovation hub.<\/p>\n\n

Liguori, together with Moretto and CFO Felipe Chippari, met with potential clients, suppliers and investors. The discussions with suppliers proved invaluable, resulting in better terms and strengthening relationships. <\/p>\n\n

On the investment front, family offices \u2013 particularly in Hong Kong \u2013 have shown immediate interest. Manufacturing in mainland China could become a reality as a means of accessing a huge market, given that \u2018Made in China\u2019 policies restrict imports and encourage local production. <\/p>\n\n

Switzerland, however, will remain the company\u2019s operational hub. \u201cMoving to Switzerland back then was a bold move, a risk,\u201d recalls Liguori. \u201cBut if I hadn\u2019t made that decision, TissueLabs wouldn\u2019t exist today.\u201d (photo by Eman Ali <\/a>on Unsplash<\/a>) <\/p>\n\n

This article is licensed under a Creative Commons Attribution\u2013NoDerivatives 4.0 International License (CC BYND 4.0)<\/strong>, allowing redistribution with attribution but no modifications.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine<\/p>\n","protected":false},"author":125,"featured_media":164715,"comment_status":"closed","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1345],"tags":[2236,1358,1331,1321,1323],"companies":[3378],"journalist":[3379],"class_list":["post-164716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-scaleup","tag-europa-en","tag-healthcare-en","tag-innovation-en","tag-lifescience-en","tag-scaleup-en","companies-tissuelabs","journalist-riccardo-ghia"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","width":150,"height":100,"crop":false,"srcset":false,"alt":"organ transplants"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","width":1024,"height":682,"crop":false,"srcset":false,"alt":"organ transplants"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","width":1280,"height":853,"crop":false,"srcset":false,"alt":"organ transplants"}},"acf":[],"yoast_head":"\nFrom patient to pioneer: the entrepreneur revolutionising organ transplants<\/title>\n<meta name=\"description\" content=\"Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"From patient to pioneer: the entrepreneur revolutionising organ transplants\" \/>\n<meta property=\"og:description\" content=\"Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T08:17:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-27T08:25:42+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"From patient to pioneer: the entrepreneur revolutionising organ transplants\",\"datePublished\":\"2026-04-27T08:17:41+00:00\",\"dateModified\":\"2026-04-27T08:25:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/\"},\"wordCount\":1128,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/eman-ali-c7TQmOOaKbM-unsplash.webp\",\"keywords\":[\"Europa\",\"healthcare\",\"innovation\",\"lifescience\",\"Scaleup\"],\"articleSection\":[\"Scaleup\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/\",\"name\":\"From patient to pioneer: the entrepreneur revolutionising organ transplants\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/eman-ali-c7TQmOOaKbM-unsplash.webp\",\"datePublished\":\"2026-04-27T08:17:41+00:00\",\"dateModified\":\"2026-04-27T08:25:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\\\/164716\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/eman-ali-c7TQmOOaKbM-unsplash.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/eman-ali-c7TQmOOaKbM-unsplash.webp\",\"width\":1280,\"height\":853,\"caption\":\"organ transplants\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"From patient to pioneer: the entrepreneur revolutionising organ transplants","description":"Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/","og_locale":"en_US","og_type":"article","og_title":"From patient to pioneer: the entrepreneur revolutionising organ transplants","og_description":"Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine","og_url":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/","og_site_name":"Startupbusiness.it","article_published_time":"2026-04-27T08:17:41+00:00","article_modified_time":"2026-04-27T08:25:42+00:00","og_image":[{"width":1280,"height":853,"url":"http:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"From patient to pioneer: the entrepreneur revolutionising organ transplants","datePublished":"2026-04-27T08:17:41+00:00","dateModified":"2026-04-27T08:25:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/"},"wordCount":1128,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","keywords":["Europa","healthcare","innovation","lifescience","Scaleup"],"articleSection":["Scaleup"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/","url":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/","name":"From patient to pioneer: the entrepreneur revolutionising organ transplants","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","datePublished":"2026-04-27T08:17:41+00:00","dateModified":"2026-04-27T08:25:42+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"Gabriel Liguori founded TissueLabs to make the production of organs a reality and to make a significant contribution to medicine","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/from-patient-to-pioneer-the-entrepreneur-revolutionising-organ-transplants\/164716\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/04\/eman-ali-c7TQmOOaKbM-unsplash.webp","width":1280,"height":853,"caption":"organ transplants"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Scaleup"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/164716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=164716"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/164716\/revisions"}],"predecessor-version":[{"id":164717,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/164716\/revisions\/164717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/164715"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=164716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=164716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=164716"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=164716"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=164716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}